Accueil   Diary - News   All news Rheonova

Rheonova

An innovative medical device for Cystic Fibrosis and COPD

 

Rheonova develops a medical device called “Rheomuco” dedicated to the pulmonary diseases market. Our technology measures complex mechanical properties of the pulmonary secretions, i.e. the viscoelasticity of sputum. The instrumentation will be easy to use and all automated: from the set-up of the sample to the data treatment. The output is a simple parameter which assesses quantitatively the state of a disease.

 

Our first customers are Biotech & Pharma companies. Rheomuco allows them to validate the effectiveness of their drug candidates obtaining pharmacodynamics data throughout in vitro studies and clinical trials.

 

The second target is the healthcare professionals who follow patients affected by a cystic fibrosis, and will use the test as a surrogate endpoint. Rheomuco makes the prognostic of the evolution of the disease possible, and discriminates the bacterial type associated with the pathology. Results will be used to adapt and anticipate treatments (including the antibiotics).

 

The third target is the pulmonologists. Rheomuco is a simple test to better diagnose and monitor the COPD (chronic obstructive pulmonary disease), an under-diagnosed disease that affects 210 million people worldwide and kills more than 3 million annually.

 

For both diseases, the main benefit for patients is a personalized follow-up of their health status, particularly with a prognostic of the exacerbation phases to avoid hospitalization and heavy emergency treatment.

 

Rheomuco substitute the indicators of the 19th century (respiratory function, patient testimony) to help professionals in their analysis and increase quality of life of patients.

 

Our next medium-term goal is to provide a miniaturized self-care medical device. Moreover, Rheonova can offer a wide range of devices to characterize other biological fluids linked to specific diseases. Knowing and understanding the properties of fluids can diagnose pathologies, prove quantitatively the efficiency of a treatment from a mechanical point of view, and play the role of a companion test.

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Service. More information... Close